---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-001112"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:33:40.673073+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q2 net loss widens to $52.6M; ARCT-154 NDA submitted in Japan

## Summary
- Q2 2023 revenue $10.5M vs $27.1M in Q2 2022; net loss $52.6M ($1.98 EPS) vs $21.6M loss ($0.82 EPS).
- Cash, equivalents and restricted cash $380.6M at June 30; cash runway extended through early 2026.
- ARCT-154 Phase 3 booster met primary endpoint; Meiji Seika Pharma submitted NDA in Japan.
- FDA granted Fast Track and Rare Pediatric Disease Designations for ARCT-810 (OTC deficiency).
- Regulatory approval received to start ARCT-032 Phase 1b study in cystic fibrosis patients.

## SEC filing metadata
- accession: 0001193805-23-001112
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/0001193805-23-001112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/e618839_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-001112
- JSON: https://secwatch.observer/filing/0001193805-23-001112.json
- Plain text: https://secwatch.observer/filing/0001193805-23-001112.txt

## Key facts
- Earnings Releases
  Arcturus Therapeutics Holdings Inc. reported the second quarter and six months ended June 30, 2023 results: revenue $10.5 million.
  - Period: the second quarter and six months ended June 30, 2023
  - Revenue: $10.5 million
  - Result: reported results
  source text: For the three months ended June 30, 2023, we reported revenue of $10.5 million compared with $27.1 million for the three months ended June 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/0001193805-23-001112-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.